Biohaven Analyst Ratings
RBC Capital Reiterates Outperform on Biohaven, Maintains $59 Price Target
Buy Rating Affirmed for Biohaven Ltd. Amidst Expansion and Progress in R&D Programs
HC Wainwright & Co. : The Biohaven (BHVN.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $59.00 to $59.00.
HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
Cantor Fitzgerald Corp.: Reiterates Biohaven's (BHVN.US) shareholding rating.
Biohaven Analyst Ratings
Analysts Conflicted on These Healthcare Names: NeueHealth Inc (NEUE), BridgeBio Pharma (BBIO) and Biohaven Ltd. (BHVN)
Biohaven Ltd. (BHVN) Gets a Buy From RBC Capital
Optimistic Outlook: Buy Rating Affirmed for Biohaven Ltd. Amid Promising Pipeline and Synergistic Drug Potential
Analysts' Top Healthcare Picks: Biohaven Ltd. (BHVN), Sarepta Therapeutics (SRPT)
Biohaven Ltd. (BHVN) Gets a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Biohaven Ltd. (BHVN) and Arrowhead Pharmaceuticals (ARWR)
Buy Rating Affirmed on Biohaven Ltd. Amidst Pipeline Potential and Upcoming Developments
Biohaven Analyst Ratings
HC Wainwright & Co. Maintains Buy on Biohaven, Lowers Price Target to $59
RBC Capital Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
Biohaven Analyst Ratings
UBS: Maintaining the Biohaven (BHVN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $59.00 to $60.00.
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Becton Dickinson (BDX)